Danaher Corporation (DHR) 2024 10-K Earnings Analysis
Danaher Corporation2024 Earnings Analysis
81/100
Danaher's FY2024 10-K shows $23.9B revenue, $3.9B net income, 59.5% gross margin, and 20.4% operating margin across Biotechnology, Life Sciences, and Diagnostics segments — the simplified three-segment perimeter following the September 2023 Veralto environmental-and-water spin-off per the spin-off press release. The 52.2% goodwill-to-assets ratio reflects Danaher Business System (DBS) M&A heritage including Pall (2015), Cepheid (2016), Beckman Coulter (2011), Cytiva (the GE Life Sciences/Biopharma assets, 2020), and Aldevron (2021) per the respective closing press releases. Rainer Blair has served as CEO since September 2020.
Filing analysis
Danaher Corporation 2024 10-K Analysis
This page reads Danaher Corporation's 2024 10-K annual report through the EarningsMoat framework: earnings quality, economic moat strength, capital allocation, and key risks. The current overall score is 81/100, or grade B.
DHR Earnings Quality
The earnings-quality module scores 84/100, with Gross Margin: 59.5%, Operating Margin: 20.4%. The core question is whether reported profit is backed by operating cash flow and recurring business economics. See the earnings quality analysis guide.
DHR Economic Moat Analysis
The moat-strength module scores 86/100, with Danaher Business System: Operating playbook, Cytiva Bioprocess: Bioprocess franchise. The test is whether the advantage can protect returns after competitors react. Read the economic moat analysis guide.
DHR Free Cash Flow vs Net Income
CF/Net Income: 1.72x is the fastest read on whether accounting earnings turn into cash. The capital-allocation module scores 82/100. For the diagnostic, start with cash flow vs net income.
DHR Key Risks from the Annual Report
The risk module scores 72/100, with Bioprocess Demand Cycle: Normalizing, Goodwill Concentration: 52.2% of assets. The goal is to separate ordinary disclosure from risks that can change margins, cash flow, leverage, or the moat itself.
Is DHR a High Quality Earnings Stock?
Based on this 2024 filing, DHR passes the first screen for high-quality earnings: the overall grade is B, and the earnings-quality score is 84/100. This is a research screen, not investment advice.
Read the report first
Understand Danaher Corporation first, then decide if it belongs on your watchlist
The DHR score, explanation, management facts, and filing sources are all here. When you want to follow more companies, review new-filing changes, or keep notes for the next review, keep more names in your watchlist.
Read the report first
Understand the company first. Keep up with every filing as your list grows.
A single report helps you judge one company. As your watchlist grows, review score, cash flow, moat, and risk changes together instead of repeating the same work.
Keep more names together
When your list grows, keep DHR with the rest of your names and review score, grade, and risk changes over time.
See how to track more namesAsk follow-up questions
Dig into cash conversion, moat evidence, capital allocation, and risk changes without rereading the full 10-K.
Ask a questionExport and revisit records
Save the DHR report as research notes you can revisit before the next filing.
Save research notesCore Dimension Scores
Evaluating competitive strength across earnings quality, moat strength, and risk sustainability
Overall Score Trend
Earnings Quality
Per the FY2024 10-K income statement, gross margin of 59.5% reflects the software-and-consumables-heavy life-sciences-tools mix post-Veralto spin, where recurring bioprocess consumables and diagnostics reagents drive margin above hardware-only medical-equipment peers.
Per the FY2024 10-K income statement, operating margin of 20.4% reflects post-pandemic bioprocess-inventory-destocking normalization in Cytiva and Pall Biotech plus continued Diagnostics segment contribution from the Cepheid franchise.
Per the FY2024 cash flow statement, OCF of $6.7B is 1.72x net income of $3.9B — the spread reflects sizable acquisition-intangible amortization on the DBS-era M&A footprint (Pall, Beckman Coulter, Cepheid, Cytiva, Aldevron per historical 10-K disclosures).
Per the FY2024 10-K segment disclosures following the September 2023 Veralto spin, Danaher now operates three segments: Biotechnology (Cytiva, Pall Biotech — bioprocessing), Life Sciences (instruments, consumables, software), and Diagnostics (Beckman Coulter, Radiometer, Cepheid molecular testing, Leica pathology).
Earnings quality scores 84/100. Per the FY2024 10-K, Danaher's $23.9B revenue produces a 59.5% gross margin and 20.4% operating margin — reflecting the life-sciences-tools-focused perimeter post the Veralto spin-off. The 1.72x CF/NI ratio is driven by M&A-legacy intangible amortization. Bioprocess-inventory destocking normalization in Biotechnology and steady Diagnostics contribution shape the current-period margin trajectory per MD&A.
Moat Strength
Per successive 10-K management disclosures and investor-day materials, the Danaher Business System (DBS) — a kaizen-based continuous-improvement framework — is the publicly-described operational playbook applied across acquired businesses. DBS implementation is cited as the principal value-capture mechanism in successive M&A transactions.
Per Danaher's 2020 Cytiva closing press release and the FY2024 Biotechnology segment MD&A, Cytiva (the former GE Life Sciences Biopharma business) provides bioprocess products (single-use bioreactors, chromatography resins, filtration) used in biologic-drug manufacturing. The bioprocess franchise is the principal growth engine disclosed in investor materials.
Per Danaher's 2016 Cepheid closing press release and the FY2024 Diagnostics segment MD&A, Cepheid GeneXpert molecular-diagnostic instruments are installed across clinical laboratories, hospitals, and public-health settings globally. The installed base drives cartridge-consumables revenue — a razor-blade model disclosed in segment-revenue metrics.
Goodwill of $40B on $78B assets equals 52.2% per the FY2024 balance sheet — elevated, reflecting the multi-decade DBS acquisition strategy. Post-Veralto spin, the remaining goodwill concentrates on the Life Sciences and Diagnostics acquired units disclosed in the balance-sheet footnote.
Moat strength scores 86/100. Per the FY2024 10-K, Danaher's competitive position rests on the Danaher Business System operating playbook applied across acquired businesses, the Cytiva bioprocess franchise that anchors the Biotechnology segment per the 2020 closing press release, the Cepheid molecular-diagnostic installed base that drives GeneXpert cartridge-consumables revenue per the 2016 closing press release, and the Beckman Coulter clinical-diagnostics franchise. The 52.2% goodwill ratio reflects the decade-long M&A accumulation partially reduced by the Veralto spin-off.
Capital Allocation
Per the FY2024 cash flow statement, FCF of $5.3B (OCF $6.7B minus capex $1.4B) supports the dividend and share-repurchase program disclosed in the capital-return section.
Per successive 10-K M&A disclosures and closing press releases, Danaher has executed a multi-decade programmatic M&A cadence applied via the DBS playbook. Recent notable deals include Aldevron (2021) and Abcam (2023) per the respective closing press releases.
Per the FY2024 dividend-history disclosure, Danaher has raised its quarterly dividend multiple times. Capital return is framed in investor-day materials as a balance with M&A-reinvestment and DBS-driven margin expansion.
Per the FY2024 balance sheet, interest-bearing debt of $16B against $2.1B cash and $5.3B FCF is manageable. The Veralto spin (September 2023 per the spin-off disclosure) simplified the capital structure by carving out the environmental/water operations and associated balance-sheet items.
Capital allocation scores 82/100. Per the FY2024 10-K, $5.3B FCF supports the dividend, share-repurchase program, and continued programmatic bolt-on M&A applied via the DBS framework (Aldevron 2021, Abcam 2023 per the respective closing press releases). The September 2023 Veralto spin-off simplified the post-spin capital structure as disclosed in the balance-sheet footnote.
Key Risks
Per the FY2024 Biotechnology segment MD&A, Cytiva bioprocess-consumables demand has been in a multi-year normalization phase following the post-COVID inventory-destocking cycle disclosed across quarterly 10-Qs and trade-press coverage. Return to growth cadence is the principal watch-item.
Per the FY2024 balance sheet, $40B goodwill concentrates impairment risk on the acquisitions carrying the largest allocated purchase-price allocations (notably Cytiva, Cepheid, Beckman Coulter, Pall). Impairment testing follows the disclosed policy.
Per the FY2024 Risk Factors, Cytiva's bioprocess-equipment demand correlates with biopharma-industry capital investment cycles. Biotech-funding conditions tracked in public BIO funding trackers flow through to equipment-order cadence.
Per the FY2024 geographic-revenue disclosures, China represents a meaningful share of Life Sciences and Diagnostics revenue. China-policy dynamics including anti-corruption campaigns disclosed in trade press affect capital-equipment purchasing cadence.
Risk profile scores 72/100 (higher = safer). Per the FY2024 10-K, the main watch-items are (1) Cytiva bioprocess demand normalization tracked in quarterly MD&A, (2) the 52.2% goodwill concentration on Cytiva, Cepheid, Beckman Coulter, Pall acquisitions, (3) biopharma-funding-cycle sensitivity per BIO public funding trackers, and (4) China geographic-revenue exposure tied to policy-cycle dynamics disclosed in trade press.
Management
Ask about this section
Ask one question here. Keep digging when the issue needs more work.
This analysis is for educational purposes only and does not constitute investment advice.